EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy

Ting-Chien Wu iD, Chen-Yi Liao, Yu-Ying Lin, Shu-Ming Chuang, Szu-Yu Liu, Chi-Hsiang Wang, Shang-Er Su, Siang-Wei Wu, Ling-I Wang, Wei-Ting Chen, Sheng-Wen Cheng, Yu-Tang Huang iD und 4 weitere

Cells · 2025

DOI: 10.3390/cells14211654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ting-Chien Wu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan. Hauptthemen laut MEDLINE: Cisplatin, Intercellular Signaling Peptides and Proteins, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung Shan Medical University, Ministry of Science and Technology, Chung Shan Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Slit2/Robo signaling pathway acts as a tumor suppressor in various cancers. This study identified an 8-amino acid peptide, LT1-3, derived from the Slit2 LamG domain, and demonstrated its ability to inhibit lung cancer cell proliferation and invasion independently of Robo receptors. Notably, LT1-3 was non-toxic to normal cells (Beas-2B, MRC5, and HUVECs). Combination treatment of LT1-3 and cisplatin synergistically inhibited the proliferation of lung cancer cells (CL1-5, A549, H1355, H460, H23, H661), but had no inhibitory effect on H1299 and H1975. Furthermore, combination therapy prolonged the median survival of tumor-bearing immunodeficient nude mice from 27.5 days (control) to 37.5 days (LT1-3 or cisplatin) and further to 47.5 days (LT1-3/cisplatin combination). The tumor suppressor TP53 positively influences LT1-3-mediated proliferation inhibition, while MAPK8 (JNK1) and PRKACA (PKA) have been identified as negative regulators. With the exception of the p53R273 variants, most TP53 mutants retained their function in this context. The p53 reactivator APR-246 restores sensitivity of p53R273H-expressing cells to LT1-3. JNK inhibition sensitizes p53-deficient or p53R273H-expressing cells to LT1-3-mediated proliferation inhibition. LT1-3, alone or in combination with a JNK inhibitor, enhances cisplatin efficacy, even in the presence of p53 mutations. Therefore, LT1-3 possesses multifunctional antitumor properties, directly inhibiting tumor cells and enhancing the efficacy of cisplatin, without causing toxicity to normal cells. Combining LT1-3 with cisplatin holds promise as a first-line therapy for lung cancer, while LT1-3 alone may be suitable for maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinIntercellular Signaling Peptides and ProteinsLung NeoplasmsAntineoplastic AgentsNerve Tissue ProteinsPeptide FragmentsHumansAnimalsCell ProliferationCell Line, TumorMice, NudeMiceSlit Homolog 2 ProteinXenograft Model Antitumor AssaysTumor Suppressor Protein p53Drug SynergismFemale

Stichwörter der Autor:innen

APR246CisplatinJNK1LT1-3Slit2p53

Substanzen

CisplatinIntercellular Signaling Peptides and ProteinsSlit Homolog 2 ProteinAntineoplastic AgentsNerve Tissue ProteinsTumor Suppressor Protein p53Peptide Fragments

Autor:innen und Institutionen

  • Institute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
  • Institute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
  • Department of Medical Laboratory and Biotechnology, Chung Shan Medical University, 110 Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
  • Division of Thoracic Surgery, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung City 407219, Taiwan.
  • Department of Chemistry, Tunghai University, Taichung, No. 1727, Sec. 4, Taiwan Boulevard, Taichung City 407224, Taiwan.
  • CSMU Lung Cancer Research Center, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.

ORCID-Profile: Ting-Chien Wu, Yu-Tang Huang, Cheng-Yen Chuang

Förderung

  • Chung Shan Medical University
  • Ministry of Science and Technology
  • Chung Shan Medical University Hospital

Zitieren

APA

Wu, T. C., Liao, C. Y., Lin, Y. Y., Chuang, S. M., Liu, S. Y., Wang, C. H., Su, S. E., Wu, S. W., Wang, L. I., Chen, W. T., Cheng, S. W., Huang, Y. T., Zheng, Y. B., Chuang, C. Y., Lung, F. D., & Chang, J. T. (2025). LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy. Cells. https://doi.org/10.3390/cells14211654

Vancouver

Wu TC, Liao CY, Lin YY, Chuang SM, Liu SY, Wang CH, et al. LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy. Cells. 2025. doi:10.3390/cells14211654

BibTeX
@article{Wu2025,
  author = {Wu, Ting-Chien and Liao, Chen-Yi and Lin, Yu-Ying and Chuang, Shu-Ming and Liu, Szu-Yu and Wang, Chi-Hsiang and Su, Shang-Er and Wu, Siang-Wei and Wang, Ling-I and Chen, Wei-Ting and Cheng, Sheng-Wen and Huang, Yu-Tang and Zheng, Yao-Bin and Chuang, Cheng-Yen and Lung, Feng-Di and Chang, Jinghua Tsai},
  title = {LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14211654}
}
Kostenlos starten →